Cue Biopharma, Inc., a Cambridge, MA-based immunotherapy company developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease, raised $26m in funding.
The round was led by MDB Capital Group.
The company will use the proceeds to accelerate development of its novel platform of T cell receptor (TCR) targeted biologics to control immune responses in patients.
Founded in 2015 and led by Daniel Passeri, M.Sc., J.D., President and Chief Executive Officer, and Steven Almo, Ph.D., Cue has developed a platform for designing biologic drugs that generate tailored immune responses from disease-relevant T cell populations by emulating the signals, or cues, delivered by the body’s antigen presenting cells.
In conjunction with the launch, Cue is announcing the members of its management team, which will be led by Daniel Passeri, M.Sc., J.D., President and Chief Executive Officer; Ronald Seidel, Ph.D., Executive Vice President, Head of Research and Development; and Rodolfo Chaparro, Ph.D., Executive Vice President, Head of Immunology. The company has also named the independent members of its Board of Directors, which include Peter Kiener, D.Phil.; Barry Simon, M.D.; and Steven McKnight, Ph.D., and formed a Scientific and Clinical Advisory Board, comprising Steven Almo, Ph.D.; Hidde Ploegh, Ph.D.; and David Baker, Ph.D.
FinSMEs
24/01/2017